Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07294625 | A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma | EARLY_PHASE1 | RECRUITING | 36 | — | — | Dec 10, 2025 | Mar 31, 2029 | Dec 19, 2025 | 5 | China |
An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.
CAR positive T cells and CAR transgene percentage of in peripheral blood after LVIVO-TaVec200 infusion
CAR positive T cells and CAR transgene percentage of in bone marrow after LVIVO-TaVec200 infusion
RP2D established through BF-BOIN design and the DLTs occurring following LVIVO-TaVec200 infusion
| Arm | Type | Description |
|---|---|---|
| LVIVO-TaVec200 product | EXPERIMENTAL | Each subject will be given a single-dose LVIVO-TaVec200 product infusion at each dose level |
| Name | Type | Description |
|---|---|---|
| LVIVO-TaVec200 product | BIOLOGICAL | Prior to infusion of the LVIVO-TaVec200 product, subjects will receive bridging therapy if needed. |
Inclusion Criteria: 1. Subjects voluntarily participate in clinical studies; Fully informed of this study and signed informed consent; Informed consent form must be obtained prior to initiation of any study-related tests or procedures that are not part of the standard treatment for the subject's di...